Associate Director, CMC; Contracts Management

Associate Director, CMC - Contracts Management

Location: Basel, Switzerland

The Director, Contracts Management must thrive in a dynamic, high-performing and collaborative environment, demonstrating a proven ability to work cross-functionally as a trusted, solutions-oriented business partner. The role will broadly support Monte Rosa Therapeutics’ (“MRTx”) global contracting function and requires substantial experience in drafting, reviewing and negotiating a wide range of agreements spanning research and development, clinical development, business development and general and administrative matters.

Responsibilities:

Independently draft, review and negotiate a wide range of contracts including without limitation Confidential Disclosure Agreements, Master Service Agreements and associated Statements of Work, Consulting Agreements, License and Collaboration Agreements, Quality Agreements, Material Transfer Agreement, Clinical Trial Agreements and Informed Consent Forms based on MRTx templates and where necessary, evaluating third party agreements against MRTx’s legal and business standards;

Subject Matter Expertise with deep experience in working with Contract Development and Manufacturing Organizations to support CMC efforts and Contract Research Organizations to support Clinical Operations efforts.

Deliver strategic, solutions-oriented advice and guidance to internal stakeholders, proactively addressing issues while balancing and managing complex legal and business considerations;

Facilitate effective coordination and communication with internal and external stakeholders, outside counsel, and counterparties to ensure seamless engagement throughout the contracting process;

Provide input and feedback concerning continual improvement and enhancement to MRTx suite of contract templates as well as efficiencies to the contracting process; and

Post execution archival and tracking of key milestones in MRTx’s contract management system.

.

Qualifications

BS/MS with 10+ years of  demonstrated experience working with legal agreements in the biotechnology industry with subject matter expertise in supporting CMC and Clinical Operations;

Excellent organizational skills; demonstrated ability to create, plan and successfully execute projects; and the ability to meet multiple deadlines in a fast-paced and deadline-driven environment;

Excellent drafting, negotiation and interpersonal skills, with high degree of emotional intelligence and strong written and verbal communication skills;

Demonstrated business acumen and sound judgment, knowing when to seek the input of others;

Commitment to integrity and ethical conduct and ability to handle confidential and proprietary information with discretion and sound judgment; and

Self-directed and proactive with an ability to work both independently and within a team environment across various functional groups and levels within the organization.

Interested Candidates may forward a CV and Cover Letter in a single PDF via our on-line portal https://www.monterosatx.com/careers/

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.